Kaposi sarcoma (KS) is one of common HIV-associated cancer. The availability of antiretroviral therapy (ART), liposomal doxorubicin, and several chemotherapy drugs have been reported the efficacy and tolerable side effect in case series and retrospective study. However, little is known the best chemotherapy regimen in this population. Thus, this systematic review intends to evaluate the best availability chemotherapy regimens for KS in HIV/AIDS patients.